TY - JOUR
T1 - Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance
AU - Amolegbe, Saliu Alao
AU - Hirano, Yui
AU - Adebayo, Joseph Oluwatope
AU - Ademowo, Olusegun George
AU - Balogun, Elizabeth Abidemi
AU - Obaleye, Joshua Ayoola
AU - Krettli, Antoniana Ursine
AU - Yu, Chengzhong
AU - Hayami, Shinya
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The use of nanocarriers in drug delivery is a breakeven research and has received a clarion call in biomedicine globally. Herein, two newly nano-biomaterials: MCM-41 encapsulated quinine (MCM-41 - QN) (1) and 3-phenylpropyl silane functionalized MCM-41 loaded QN (pMCM-41 - QN) (2) were synthesized and well characterized. 1 and 2 along with our two already reported nano-antimalarial drugs (MCM-41 - ATS) (3) and 3-aminopropyl silane functionalized MCM-41 contained ATS (aMCM-41 - ATS) (4) were screened in vitro for their activity against P. falciparium W2 strain, cytotoxicity against BGM cells and in vivo for their activity against Plasmodium bergheiNK65. 1 has the highest antimalarial activity in vivo against P. berghei NK65, (ED50: < 0.0625 mg/kg body weight) and higher mean survival time compared to the other nano biomaterials or unencapsulated drugs at doses higher than 0.0625 mg/kg body weight. This encapsulation strategy of MCM-41 - QN (1) stands very useful and effective in delivering the drug to the target cells compared to other delivery systems and therefore, this encapsulated drug may be considered for rational drug design.
AB - The use of nanocarriers in drug delivery is a breakeven research and has received a clarion call in biomedicine globally. Herein, two newly nano-biomaterials: MCM-41 encapsulated quinine (MCM-41 - QN) (1) and 3-phenylpropyl silane functionalized MCM-41 loaded QN (pMCM-41 - QN) (2) were synthesized and well characterized. 1 and 2 along with our two already reported nano-antimalarial drugs (MCM-41 - ATS) (3) and 3-aminopropyl silane functionalized MCM-41 contained ATS (aMCM-41 - ATS) (4) were screened in vitro for their activity against P. falciparium W2 strain, cytotoxicity against BGM cells and in vivo for their activity against Plasmodium bergheiNK65. 1 has the highest antimalarial activity in vivo against P. berghei NK65, (ED50: < 0.0625 mg/kg body weight) and higher mean survival time compared to the other nano biomaterials or unencapsulated drugs at doses higher than 0.0625 mg/kg body weight. This encapsulation strategy of MCM-41 - QN (1) stands very useful and effective in delivering the drug to the target cells compared to other delivery systems and therefore, this encapsulated drug may be considered for rational drug design.
UR - https://www.scopus.com/pages/publications/85042176238
U2 - 10.1038/s41598-018-21351-8
DO - 10.1038/s41598-018-21351-8
M3 - 文章
C2 - 29449583
AN - SCOPUS:85042176238
SN - 2045-2322
VL - 8
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 3078
ER -